Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 6, 2024
Product Development
Alzheimer’s roundup: Clinical progress and setbacks at CTAD
Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | May 4, 2022
Product Development
Biogen plots pipeline strategy as CEO readies to depart
Interim head of R&D says the biotech plans to stay the course in neuroscience, at least for now
BioCentury | Oct 5, 2015
Finance
Asceneuron's clinical path
Why Sofinnova Partners led preclinical tau biology play Asceneuron's A round
BioCentury | Mar 2, 2015
Emerging Company Profile
The road to Tau
Asceneuron plans to show power of tau in AD by first tackling Orphan tauopathy
BioCentury | Sep 17, 2012
Tools & Techniques
BMS's high carb diet
BMS hopes Summit's carbohydrate tech can generate stable, target-specific drugs
Items per page:
1 - 10 of 14